<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04244175</url>
  </required_header>
  <id_info>
    <org_study_id>CVL-865-SZ-001</org_study_id>
    <secondary_id>2019-002576-14</secondary_id>
    <nct_id>NCT04244175</nct_id>
  </id_info>
  <brief_title>A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter Trial of CVL-865 as Adjunctive Therapy in Adults With Drug-Resistant Focal Onset Seizures (REALIZE Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cerevel Therapeutics, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cerevel Therapeutics, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy, safety, and tolerability profile of&#xD;
      CVL-865 as adjunctive treatment in participants with drug-resistant focal onset seizures.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 27, 2020</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Ratio (RRatio)</measure>
    <time_frame>Day 71</time_frame>
    <description>Response Ratio (RRatio), calculated as RRatio=(T-B)/(T+B) Ã—100, where T represents the focal onset seizure frequency rate per week in the Maintenance Phase and B represents the focal onset seizure frequency rate per week in the Baseline Period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Focal Onset Seizure Frequency per Week over the Maintenance Phase</measure>
    <time_frame>Baseline up to Day 71</time_frame>
    <description>Seizure frequency is defined as the total number of focal onset seizures over the treatment period of interest divided by the total number of days with no missing seizure counts in the corresponding period multiplied by 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with 50 Percent (%) Responder Rate</measure>
    <time_frame>Day 71</time_frame>
    <description>Defined as the percent of participants with at least a 50% reduction in the Maintenance Phase focal onset seizure frequency rate relative to the Baseline Period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Seizure-free Participants</measure>
    <time_frame>Baseline up to Day 71</time_frame>
    <description>Seizure freedom is defined as the absence of all seizure regardless of seizure type.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seizure Rate over Time</measure>
    <time_frame>Baseline up to Day 71</time_frame>
    <description>Seizure frequency is defined as the total number of focal onset seizures over the treatment period of interest divided by the total number of days with no missing seizure counts in the corresponding period multiplied by 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's Global Impression of Change (PGIC) Score at Days 15, 43 and 71</measure>
    <time_frame>Baseline, Day 15, 43 and 71</time_frame>
    <description>The self-report measure Patient's Global Impression of Change (PGIC) reflects a participant's belief about the efficacy of treatment. It is a 7-point scale depicting a participant's rating of overall improvement where 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse and 7 = very much worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Clinical Global Impression-Severity of Symptoms Scale (CGI-S) Score at Day 15, 43 and 71</measure>
    <time_frame>Baseline, Day 15, 43 and 71</time_frame>
    <description>The CGI-S is an observer-rated scale that will be used to measure symptom severity. It is a 7-point scale depicting a participants rating of overall improvement. Participants rate their change as 0 = not assessed; 1 = normal, not at all ill; 2 = borderline ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Clinical Global Impression-Improvement Scale (CGI-I) Score at Day 15, 43 and 71</measure>
    <time_frame>Baseline, Day 15, 43 and 71</time_frame>
    <description>The CGI-I is an observer-rated scale that will be used to measure the participant's symptom severity compared with before initiation of treatment with IMP. It is a 7-point scale depicting a participant's change from baseline in symptom severity using the following response choices: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Quality of Life in Epilepsy -31 (QOLIE-31) Overall Score at Day 71</measure>
    <time_frame>Baseline, Day 71</time_frame>
    <description>The Quality of Life in Epilepsy - 31 (QOLIE-31) contains 7 multi-item scales that tap the following health concepts: emotional well-being, social functioning, energy/fatigue, cognitive functioning, seizure worry, medication effects, and overall quality of life. A QOLIE-31 overall score is obtained using a weighted average of the multi-item scale scores. The QOLIE-31 also includes a single item that assessed overall health. The QoLIE-31 score range is from 0 to 100 with a higher score indicating a better outcome for quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Health Utilities Index (HUI) Utility Score at Day 71</measure>
    <time_frame>Baseline, Day 71</time_frame>
    <description>The Health Utilities Index (HUI) is a rating scale used to measure general health status and health-related quality of life. In HUI, utility values range from -0.03 and -0.36 for the HUI-2 and HUI-3, respectively, to 1.00. A health utility value of 1.00 indicates perfect health while a score of 0.00 indicates death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Clinically Significant Changes in Electrocardiogram (ECGs)</measure>
    <time_frame>Baseline to Day 92 or early termination</time_frame>
    <description>12-lead ECGs recordings will be obtained after the participant has been supine and at rest for at least 5 minutes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Clinically Significant Changes in Vital Sign Measurements</measure>
    <time_frame>Baseline to Day 92 or early termination (ET)</time_frame>
    <description>Vital signs will be measured with the participant in a sitting/semi-recumbent position after 5 minutes rest and will include temperature, systolic and diastolic blood pressure, and heart rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Clinically Significant Changes in Physical and Neurological Examination Results</measure>
    <time_frame>Baseline to Day 92 or early termination (ET)</time_frame>
    <description>Number of participants with clinically significant changes in physical and neurological examination results will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Positive Response to Columbia Suicide-Severity Rating Scale (C-SSRS)</measure>
    <time_frame>From first dose of study drug up to Day 120 (follow up period)</time_frame>
    <description>The C-SSRS rates an individual's degree of suicidal ideation (SI) on a scale, ranging from &quot;wish to be dead&quot; to &quot;active suicidal ideation with specific plan and intent.&quot; The scale identifies SI severity and intensity, which may be indicative of an individual's intent to commit suicide. C-SSRS SI severity subscale ranges from 0 (no SI) to 5 (active SI with plan and intent).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Positive Response to Modified Clinical Institute Withdrawal Assessment - Benzodiazepines (mCIWA-B)</measure>
    <time_frame>Day 71 up to Day 120</time_frame>
    <description>The modified Clinical Institute Withdrawal Assessment - Benzodiazepines (mCIWA-B) is a sensitive instrument to measure withdrawal under conditions where there is a taper of medication (rather than abrupt discontinuation). It consists of 17-items that monitor the type and severity of BZD withdrawal symptoms such as irritability, fatigue, appetite, and sleeplessness. The total score ranges from 1 to 68 with higher scores indicating more severe withdrawal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment Emergent Adverse Event (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)</measure>
    <time_frame>From first dose of study drug up to Day 120 (follow up period)</time_frame>
    <description>TEAEs will include abuse-related AEs and AEs related to medication handling irregularities (MHIs). Number of Participants With TEAEs and TESAEs will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentrations of CVL-865</measure>
    <time_frame>Day 15, Day 43, Day 71, Day 92 and/or early termination (ET)</time_frame>
    <description>Plasma concentration of CVL-865 at Day 15, Day 43, Day 71, Day 92 and/or early termination (ET) will be assessed.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Seizures</condition>
  <arm_group>
    <arm_group_label>High Dose: CVL-865 25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive CVL-865 tablets orally twice daily (BID) up to the maximum dose of 25 milligrams (mg) until Day 92 during the treatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Dose: CVL-865 7.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive CVL-865 tablets orally BID up to the maximum dose of 7.5 mg until Day 92 during the treatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive a placebo matched to CVL-865 tablets orally BID until Day 92 during the treatment period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CVL-865</intervention_name>
    <description>Participants will receive CVL-865 tablets orally BID up to the maximum dose of 7.5 mg BID or 25 mg BID during the treatment period.</description>
    <arm_group_label>High Dose: CVL-865 25 mg</arm_group_label>
    <arm_group_label>Low Dose: CVL-865 7.5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will receive CVL-865 matched placebo tablet orally BID during the treatment period.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants with a diagnosis of epilepsy with focal onset, as defined in the&#xD;
             International League Against Epilepsy (ILAE) Classification of Seizures, focal aware&#xD;
             (except participants with only focal aware seizures without a motor component), focal&#xD;
             impaired awareness, and focal to bilateral tonic-clonic seizures for at least 2 years&#xD;
             prior to signing the Informed Consent Form (ICF)&#xD;
&#xD;
          -  Participants must have history of an average of 4 or more spontaneous and observable&#xD;
             focal onset, as defined in the ILAE Classification of Seizures, focal aware (except&#xD;
             participants with only focal aware seizures without a motor component), focal impaired&#xD;
             awareness, and focal to bilateral tonic-clonic seizures per 28-day period for at least&#xD;
             3 months (84 days) prior to signing the ICF&#xD;
&#xD;
          -  Participants who have tried and failed at least 2 appropriate Anti- epileptic drugs&#xD;
             (AEDs) in the past and also currently taking 1 to 3 permitted AEDs at a stable dose&#xD;
             for 4 Weeks prior to the Screening Visit&#xD;
&#xD;
          -  Participants with a minimum of 8 focal onset, focal aware, focal impaired awareness,&#xD;
             or focal to bilateral tonic-clonic seizures during the 8 week baseline period with no&#xD;
             21-day period free of any of these seizure types&#xD;
&#xD;
          -  Participants must have had magnetic resonance imaging or contrast enhance computed&#xD;
             tomography scan of the brain that demonstrated no progressive structural central&#xD;
             nervous system abnormality at the time of the diagnosis of epilepsy&#xD;
&#xD;
          -  Participants must have a body mass index (BMI) of 17.5 to 40.0 kilogram per meter&#xD;
             square (kg/m^2) and a total body weight greater than (&gt;) 50 kilograms (kg) [110 pounds&#xD;
             (lbs)]&#xD;
&#xD;
          -  Women of childbearing potential must agree to use an effective method of contraception&#xD;
             from signing of informed consent throughout the duration of the study and for 30 days&#xD;
             post last dose&#xD;
&#xD;
          -  Male must agree to use condom during treatment and until the end of relevant systemic&#xD;
             exposure in the male participant for 94 days following the last dose with&#xD;
             Investigational Manufacturing Product (IMP)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants with (genetic) idiopathic generalized epilepsies or combined generalized&#xD;
             and focal epilepsies, including a history of Lennox-Gastaut Syndrome&#xD;
&#xD;
          -  Participants with a history of seizures over the past 12 months that occur at such a&#xD;
             high frequency they cannot be counted (eg, repetitive seizures, cluster seizures)&#xD;
&#xD;
          -  Participants with a history of psychogenic non-epileptic seizures within the year&#xD;
             prior to signing the ICF&#xD;
&#xD;
          -  Participants with a history of status epilepticus within 5 years prior to signing the&#xD;
             ICF&#xD;
&#xD;
          -  Participants with a history of neurosurgery for seizures less than 1 year prior to&#xD;
             signing the ICF, or radiosurgery less than 2 years prior to signing the ICF&#xD;
&#xD;
          -  Participants with a current history of significant cardiovascular, pulmonary,&#xD;
             gastrointestinal, renal, hepatic, metabolic, hematological, immunological, or&#xD;
             neurological (excluding focal onset epilepsy) disease&#xD;
&#xD;
          -  Participants who test positive for human immunodeficiency virus (HIV), hepatitis B&#xD;
             and/or or hepatitis C infection&#xD;
&#xD;
          -  Participants with a 12-lead ECG demonstrating : QT interval corrected for heart rate&#xD;
             using Fridericia's formula &gt;450 milliseconds (msec) (average of 3 ECGs obtained at the&#xD;
             Screening Visit); QRS interval &gt;120 msec at the Screening Visit assessed by central&#xD;
             reader&#xD;
&#xD;
          -  Participants with abnormal laboratory test results which includes (Aspartate&#xD;
             aminotransferase (AST) or Alanine aminotransferase (ALT) elevated to &gt;2 Ã— Upper limit&#xD;
             of normal range (ULN); Total bilirubin greater than or equal to (&gt;=)1.5 Ã— ULN;&#xD;
             Females: Hemoglobin &lt;11 gram per deciliter (g/dL); Males: hemoglobin &lt;12 g/dL; White&#xD;
             blood cell (WBC) count &lt;3.0 x 10 power 9 per liter (10^9/L); Neutrophil count &lt;2.0 x&#xD;
             10^9/L; Platelet count &lt;150 Ã— 10^9/L&#xD;
&#xD;
          -  Use of prohibited medications as listed in the protocol in the absence of appropriate&#xD;
             washout phase or the likelihood of requiring treatment during the study period with&#xD;
             drugs not permitted by the study protocol&#xD;
&#xD;
          -  Participants taking any drug that is a sensitive P-glycoprotein (P-gp) and Breast&#xD;
             cancer resistance protein (BCRP) substrate&#xD;
&#xD;
          -  Female participants who are breastfeeding and/or who have a positive pregnancy test&#xD;
             result prior to receiving IMP&#xD;
&#xD;
          -  Participants who are known to be allergic or hypersensitive to the IMP or any of its&#xD;
             components&#xD;
&#xD;
          -  Participants who have participated in any clinical trial within 60 days prior to&#xD;
             signing the ICF or who have participated in more than 2 clinical trials within the&#xD;
             year prior to signing the ICF&#xD;
&#xD;
          -  Participants with difficulty swallowing&#xD;
&#xD;
          -  Participants who answer &quot;Yes&quot; on the C-SSRS Suicidal Ideation Item 4 (Active Suicidal&#xD;
             Ideation with Some Intent to Act, Without Specific Plan) and whose most recent episode&#xD;
             meeting criteria for this C-SSRS Item 4 occurred within the last 6 months, OR Subjects&#xD;
             who answer &quot;Yes&quot; on the C-SSRS Suicidal Ideation Item 5 (Active Suicidal Ideation with&#xD;
             Specific Plan and Intent) and whose most recent episode meeting criteria for this&#xD;
             CSSRS Item 5 occurred within the last 6 months OR Subjects who answer &quot;Yes&quot; on any of&#xD;
             the 5 C-SSRS Suicidal Behavior Items (actual attempt, interrupted attempt, aborted&#xD;
             attempt, preparatory acts, or behavior) and whose most recent episode meeting criteria&#xD;
             for any of these 5 C-SSRS Suicidal Behavior Items occurred in the last 2 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ann Dandurand, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cerevel Therapeutics, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Los Angeles, California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danny Benmoshe</last_name>
      <phone>818-943-6635</phone>
      <email>drbenmoshe@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>New Haven, Connecticut</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hamada Altalib</last_name>
      <phone>203-737-5098</phone>
      <email>hamada.hamid@yale.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gulf Breeze, Florida</name>
      <address>
        <city>Gulf Breeze</city>
        <state>Florida</state>
        <zip>32561-4458</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weldon Mauney</last_name>
      <phone>850-934-1299</phone>
      <email>WMauney@nwflcrg.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jacksonville, Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Tatum</last_name>
      <phone>904-953-2498</phone>
      <email>tatum.william@mayo.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Miami, Florida</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kamil Detyniecki</last_name>
      <phone>305-243-6732</phone>
      <email>kamil.detyniecki@med.miami.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Miami, Florida</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33156</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Orlando, Florida</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed Sadek</last_name>
      <phone>352-317-4093</phone>
      <email>ahsadek@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Port Charlotte, Florida</name>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <zip>33952</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George Li</last_name>
      <phone>941-623-9744</phone>
      <email>gli@medsolcrc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tallahassee, Florida</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ricardo Ayala</last_name>
      <phone>850-878-8121</phone>
      <email>neuroclinic@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tampa, Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Selim Benbadis</last_name>
      <phone>813-259-8577</phone>
      <email>sbenbadi@health.usf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Suwanee, Georgia,</name>
      <address>
        <city>Suwanee</city>
        <state>Georgia</state>
        <zip>30024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Lesch</last_name>
      <phone>770-814-9455</phone>
      <email>dlesch@ganeurosleep.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Honolulu, Hawaii</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kore Liow</last_name>
      <phone>808-564-6141</phone>
      <email>kliow@hawaiineuroscience.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Boise, Idaho</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Wechsler</last_name>
      <phone>208-275-8585</phone>
      <email>wechsler5@me.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Urbana, Illinois</name>
      <address>
        <city>Urbana</city>
        <state>Illinois</state>
        <zip>61801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Graham Huesmann</last_name>
      <phone>217-904-7276</phone>
      <email>graham.huesmann@carle.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Winfield, Illinois</name>
      <address>
        <city>Winfield</city>
        <state>Illinois</state>
        <zip>60190</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roy Sucholeiki</last_name>
      <phone>630-933-7581</phone>
      <email>Roy.Sucholeiki@nm.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lexington, Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40504</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Toufic Fakhoury</last_name>
      <phone>859-313-4989</phone>
      <email>touficfakhoury@catholichealth.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Scarborough, Maine</name>
      <address>
        <city>Scarborough</city>
        <state>Maine</state>
        <zip>04074</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heidi Henninger</last_name>
      <phone>207-396-8675</phone>
      <email>hhenninger@mmc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baltimore, Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory Krauss</last_name>
      <phone>410-502-5570</phone>
      <email>gkrauss@jhmi.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bethesda, Maryland</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pavel Klein</last_name>
      <phone>301-530-9744</phone>
      <email>KleinP@Epilepsydc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Boston, Massachusetts</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Cole</last_name>
      <phone>617-726-3311</phone>
      <email>cole.andrew@mgh.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Louis, Missouri</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edward Hogan</last_name>
      <phone>314-362-7845</phone>
      <email>hoganre@wustl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hackensack, New Jersey</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Segal</last_name>
      <phone>201-343-6676</phone>
      <email>esegal@epilepsygroup.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bronx, New York</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alex Boro</last_name>
      <phone>718-920-4898</phone>
      <email>aboro@montefiore.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mineola, New York</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shicong Ye</last_name>
      <phone>516-663-2815</phone>
      <email>Shicong.Ye@nyulangone.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>New York</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claude Steriade</last_name>
      <phone>216-225-2412</phone>
      <email>claude.steriade@nyulangone.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>New York</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruben Kuzniecky</last_name>
      <phone>516-325-7022</phone>
      <email>rkuzniecky@northwell.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rochester, New York</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trenton Tollefson</last_name>
      <phone>585-276-3439</phone>
      <email>trenton_tollefson@urmc.rochester.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Syracuse, New York</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Beach</last_name>
      <phone>315-464-4243</phone>
      <email>BEACHR@upstate.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbus, Ohio</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43221</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaysingh Singh</last_name>
      <phone>614-366-4477</phone>
      <email>Jaysingh.Singh@osumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Toledo, Ohio</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43614</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Imran Ali</last_name>
      <phone>419-383-3801</phone>
      <email>imran.ali@utoledo.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oklahoma City, Oklahoma</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Veronique Sebastian</last_name>
      <phone>405-843-0374</phone>
      <email>vs@soonerclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Philadelphia, Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Gelfand</last_name>
      <phone>917-748-4640</phone>
      <email>michael.gelfand@uphs.upenn.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Philadelphia, Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Sperling</last_name>
      <phone>215-955-1222</phone>
      <email>michael.sperling@jefferson.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charleston, South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johnathan Halford</last_name>
      <phone>843-792-9016</phone>
      <email>halfordj@musc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cordova, Tennessee</name>
      <address>
        <city>Cordova</city>
        <state>Tennessee</state>
        <zip>38018</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nashville, Tennessee</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bassel Abou-Khalil</last_name>
      <phone>615-343-0473</phone>
      <email>bassel.abou-khalil@vumc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Salt Lake City, Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amir Arain</last_name>
      <phone>801-587-7757</phone>
      <email>amir.arain@hsc.utah.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Camperdown, New South Wales</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Armin Nikpour</last_name>
      <phone>+61 2 9515 3928</phone>
      <email>armin@sydneyneurology.com.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Randwick, New South Wales</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ernest Somerville</last_name>
      <phone>+61 2 9382 3805</phone>
      <email>Ernest.Somerville@health.nsw.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Westmead, New South Wales</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manori Wijayath</last_name>
      <phone>+61 2 8890 6753</phone>
      <email>manori.wijayath@health.nsw.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Herston, Queensland</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Reutens</last_name>
      <phone>+61 7 3365 4237</phone>
      <email>david.reutens@cai.uq.edu.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bedford Park, SA</name>
      <address>
        <city>Bedford Park</city>
        <state>South Australia</state>
        <zip>5042</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Frasca</last_name>
      <phone>+61 08 8204 4187</phone>
      <email>joseph.frasca@sa.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Box Hill, Victoria</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Carney</last_name>
      <phone>+61 3 9095 2425</phone>
      <email>patrick.carney2@easternhealth.org.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fitzroy, Victoria</name>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendyl D'Souza</last_name>
      <phone>+61 3 9231 3665</phone>
      <email>wendyl.dsouza@svha.org.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Heidelberg, Victoria</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saul Mullen</last_name>
      <phone>+61 3 9035 7137</phone>
      <email>Saul.mullen@unimelb.edu.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Melbourne, Victoria</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terence OBrien</last_name>
      <phone>+61 3 9076 2596</phone>
      <email>te.obrien@alfred.org.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Parkville, Victoria</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piero Perucca</last_name>
      <phone>+61 3 9342 7722</phone>
      <email>Piero.Perucca@mh.org.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Malaga,</name>
      <address>
        <city>MÃ¡laga</city>
        <state>Andalusia</state>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pedro Serrano-Castro</last_name>
      <phone>+34 671597250</phone>
      <email>pedro.serrano.c@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Barcelona, Catalunya</name>
      <address>
        <city>Barcelona</city>
        <state>Catalonia</state>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rodrigo Alberto Rocamora</last_name>
      <phone>+34 93 248 3727</phone>
      <email>rrocamora@psmar.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Terrassa</name>
      <address>
        <city>Terrassa</city>
        <state>Catalonia</state>
        <zip>08222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meritxell Martinez Ferri</last_name>
      <phone>+34 937 365 050</phone>
      <phone_ext>300</phone_ext>
      <email>mmartinezf@mutuaterrassa.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Navarra</name>
      <address>
        <city>Navarro</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Asier Gomez Ibanez</last_name>
      <phone>+34 913508677</phone>
      <email>agomezi@unav.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>8035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuel Toledo</last_name>
      <phone>+34 934 894 257</phone>
      <email>mtoledo@vhebron.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Madrid</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angel Aledo</last_name>
      <phone>+34 91 387 5250</phone>
      <email>aaledo@neurologiaclinica.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Madrid</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irene Garcia Morales</last_name>
      <phone>+34 913 303 511</phone>
      <email>garciamorales2@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sevilla</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Jesus Rodriguez Uranga</last_name>
      <phone>+34 666 465 492</phone>
      <email>uranganeuro@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincente Villanueva</last_name>
      <phone>+34 961 244 000</phone>
      <email>vevillanuevah@yahoo.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://realizestudy.com/</url>
    <description>The REALIZE Study website provides information on the nature of the study's research, a brief overview of key entry criteria, study design and information on participating sites.</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 24, 2020</study_first_submitted>
  <study_first_submitted_qc>January 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 28, 2020</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CVL-865</keyword>
  <keyword>Anti-epileptic drugs (AEDs)</keyword>
  <keyword>Focal epilepsy</keyword>
  <keyword>Î³-aminobutyric acid (GABA)</keyword>
  <keyword>Partial seizure</keyword>
  <keyword>PF-06372865</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Seizures</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

